Angelika Stevens, PA
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,634 of the $8,492 with a category attached, or 78.1%. It is spread thinly across 32 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,951, more than ten times the $174 reported in 2021. Among medical clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $32.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Inspire Medical Systems, Inc.$2K
- ZOLL Respicardia, Inc.$1K
- Grifols USA, LLC$480
- Regeneron Healthcare Solutions, Inc.$404
- Jazz Pharmaceuticals Inc.$381
- plus $2K from 26 others
What the payments were for
- Travel & lodging$1,48718%
- Food & beverage$6,63478%
- Education$3714%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 63 | $1,921 |
| Inspire Medical Systems, Inc. | 14 | $1,576 |
| ZOLL Respicardia, Inc. | 5 | $1,431 |
| Grifols USA, LLC | 22 | $480 |
| Regeneron Healthcare Solutions, Inc. | 23 | $404 |
| Jazz Pharmaceuticals Inc. | 15 | $381 |
| Amgen | 16 | $337 |
| Harmony Biosciences LLC | 15 | $278 |
| Insmed, Inc. | 14 | $249 |
| Mallinckrodt Hospital Products Inc. | 5 | $197 |
| Boehringer Ingelheim | 9 | $174 |
| Actelion Pharmaceuticals US, Inc. | 8 | $154 |
| Electromed, Inc. | 8 | $110 |
| GSK | 5 | $88 |
| Merck | 3 | $85 |
| United Therapeutics Corporation | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $70 |
| Baxter Healthcare | 3 | $60 |
| Verona Pharma, Inc. | 3 | $56 |
| Mylan Specialty L.p. | 2 | $38 |
| Sanofi | 2 | $32 |
| Philips North America LLC | 2 | $29 |
| Genentech USA, Inc. | 2 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Resmed Corp | 1 | $24 |
| Endo USA, Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Viatris Specialty LLC | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$1,368
- Inspire$998
- FASENRA$903
- BREZTRI$903
- TEZSPIRE$666
- AIRSUPRA$369
- ANDEXXA$369
- Inspire Upper Airway Stimulation System$141
How this compares
$8,492 in reported general payments places this provider in the 95th percentile of 216 medical providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,989 |
| Modafinil | 48 | $4,324 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKAnoro Ellipta | $88 | $8,98919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 medical providers in Nebraska.
Other medical in Omaha
- Kelly HooverOmaha$16K
- Jacob RidderOmaha$12K
- Jennelea MontanezOmaha$8K
- Kristina DadaOmaha$7K
- Saundra BrennanOmaha$6K
- Collin HortonOmaha$6K
- Karla LessmanOmaha$5K
- Lynn McLaughlinOmaha$4K
- Hannah PickOmaha$4K
- Rebecca BertucciOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.